Skip to main content
Premium Trial:

Request an Annual Quote

Epizyme Partnering With Quest Diagnostics for Lymphoma Mutation Testing

NEW YORK — Biopharma company Epizyme said Wednesday that it has launched a collaboration with Quest Diagnostics to provide mutation testing for lymphoma patients.

Called the EZH2Now Testing Program, the initiative aims to improve patient access to EZH2 mutation testing for patients with relapsed or refractory follicular lymphoma.

EZH2 is an epigenetic regulator of B-cell identity and is involved in normal B-cell biology and the pathogenesis of follicular lymphoma. It is an emerging drug target, and while oncogenic dependence on EZH2 can occur regardless of mutation status, single-gene testing could help physicians better characterize their patients' cancer.

Patients who qualify for the EZH2Now Testing Program will receive testing services at no cost.

"We are committed to broadening access to diagnostic insights for patients and providers everywhere," Kristie Dolan, general manager, oncology franchise at Quest, said in a statement. "Our participation in the EZH2Now Testing Program not only delivers on this goal, but also highlights Quest Diagnostics’ commitment to innovations in oncology and advanced diagnostics that improve patient care, as well as our deep specialization in hematopathology."

Financial and other terms of the agreement were not disclosed.

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.